Skip to main content

Table 1 The general characteristics of NMOSD patients

From: Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders

Variable Patients (n = 32)
Mean Age of onset, year 33.28 (15–62)
Sex (n%)
 Female 30 (93.75%)
 Male 2 (6.25%)
Mean BMI 24.17 (17.57–31.65)
Mean Disease duration, months 85.56 (19–266)
Mean Duration of AZA therapy, months 21.50 (12–40)
Clinical symptoms at onset (n%)
 Optic neuritis 21 (65.6%)
 Bilateral Optic neuritis 17 (53.13%)
 Myelitis 29 (90.6%)
 Optic neuritis and Myelitis 19 (59.3%)
Mean Pre-therapy EDSS score 5.21 ± 0.24 (2.5–8)
Mean Post- therapy EDSS score 2.57 ± 0.33 (0–7)
Mean Concentration of CSF protein, mg/dl 40.41 ± 32.67 (12–184)
Mean Concentration of CSF IgG, mg/ml 0.04 ± 0.03 (0.01–0.19)
CSF IgG index (n%) 0.53 ± 0.10 (0.39–0.83)
Serum anti-AQP4 antibodies (n%) 14 (43.75%)
Mean Concentration of 6-TGNs, pmol/8 × 108 RBC 202.03
Mean Concentration of MMPNs, pmol/8 × 108 RBC 1618.90
Relapse, n% 12/32 (37.5%)
Pre- therapy ARR 1.42 ± 0.23 (0.2–3.5)
Post- therapy ARR 0.36 ± 0.09 (0–1.72)
  1. NMOSD Neuromyelitisoptica spectrum disorders, AZA Azathioprine, AQP4 anti-aquaporin 4, BMI Body mass index, ARR Annual relapse rate, EDSS Expanded disability status scale, CSF cerebrospinal fluid, IgG Immunoglobulin G